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Unfortunately, many errors were identified in the published
article. The original article was corrected.
Article Title, which previously read:
Prevalence of Use and Cost of Biological Drugs for
Cancer Treatment: A 5-Year Picture from Southern Italy
Should read:
Prevalence of Use and Cost of Biological and Non-Bio-
logical Targeted Therapies for Cancer Treatment: A 5-Year
Picture from Southern Italy
Article running header, which previously read:
5-Year Prevalence of Use and Costs of Biologics in
Oncology in Southern Italy
Should read:
Cost of Biological and Non-Biological Targeted Ther-
apies in Oncology in Southern Italy
Abstract: Background and Objectives, which previously
read:
Considering the clinical and economic burden of biological
drugs in cancer treatment, it is necessary to explore how
these drugs are used in routine care in Italy and how they
affect the sustainability of the National Health Services.
This study aimed to investigate the prevalence of use and
costs of biological drugs for cancer treatment in a general
population of Southern Italy in the years 2010–2014.
Should read:
Considering the clinical and economic burden of bio-
logical and non-biological targeted therapies in cancer
treatment, it is necessary to explore how these drugs are
used in routine care in Italy and how they affect the sus-
tainability of the National Health Services. This study
aimed to investigate the prevalence of use and costs of
biological and non-biological targeted therapies for cancer
treatment in a general population of Southern Italy in the
years 2010–2014.
The online version of the original article can be found under https://
doi.org/10.1007/s40261-017-0591-3.
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Abstract: Methods, 2nd sentence, which previously read:
In this study, users of biological drugs for cancer
treatment were characterized and the prevalence of use and
costs were calculated over time.
Should read:
In this study, users of biological and non-biological
targeted therapies for cancer treatment were characterized
and the prevalence of use and costs were calculated over
time.
Abstract: Conclusions, which previously read:
In recent years, the use and costs of biological drugs in
cancer patients dramatically increased in a large population
from Southern Italy. This trend may be counterbalanced by
adopting biosimilars once they are available. Claims
databases represent a valid tool to monitor the uptake of
newly marketed biological drugs and biosimilars.
Should read:
In recent years, the use and costs of biological and non-
biological targeted therapies in cancer patients dramatically
increased in a large population from Southern Italy. This
trend may be counterbalanced by adopting biosimilars once
they are available. Claims databases represent a valid tool
to monitor the uptake of newly marketed biological drugs
and biosimilars as well as other non-biological targeted
therapies.
Key Points, 1st Key Point, which previously read:
In recent years, the use of biological drugs for cancer
treatment rapidly increased and the corresponding costs
almost doubled from €6.6 to €13.6 million.
Should read:
In recent years, the use of biological and non-biological
targeted therapies for cancer treatment rapidly increased
and the corresponding costs almost doubled from €6.6 to
€13.6 million.
Key Points, 3rd Key Point, which previously read:
Claims databases may represent a valid tool for moni-
toring the uptake of newly marketed biological drugs and
biosimilars.
Should read:
Claims databases may represent a valid tool for moni-
toring the uptake of newly marketed biological drugs and
biosimilars as well as other innovative targeted therapies.
Section 1, 2nd paragraph, 1st sentence, which previously
read:
Considering the clinical and economic burden of bio-
logical drugs in cancer treatment, it is necessary to explore
how these drugs are used in routine care and how they
affect the sustainability of the National Health Services
(NHSs).
Should read:
Considering the clinical and economic burden of bio-
logical and non-biological targeted therapies in cancer
treatment, it is necessary to explore how these drugs are
used in routine care and how they affect the sustainability
of the National Health Services (NHSs).
Section 1, Introduction, 4th paragraph, 1st sentence,
which previously read:
The aim of this retrospective, observational study was to
analyze the use and costs of biologic drugs for cancer treat-
ment in a large area of Southern Italy in the years 2010–2014.
Should read:
The aim of this retrospective, observational study was to
analyze the use and costs of biological and non-biological
targeted therapies for cancer treatment in a large area of
Southern Italy in the years 2010–2014.
Section 2.1, 1st paragraph, last line, which previously
read:
Each of these centers provided information on the total
use of biological drugs for cancer treatment from all resi-
dents in Messina Province (Southern Italy).
Should read:
Each of these centers provided information on the total
use of biological and non-biological targeted therapies for
cancer treatment from all residents in Messina Province
(Southern Italy).
Section 2.1, 2nd paragraph, 3rd, 4th and sentences,
which previously read:
In outpatients, systemic biological drugsadministered as
subcutaneous injections or orally are dispensed by the
hospital pharmacists to the patient, who will self-admin-
ister the drug. Systemic biological drugs administered as an
intravenous infusion are administered exclusively in the
hospital setting, even to outpatients. However, the dis-
pensing of biological drugs to outpatients is recorded at
patient level through the dispensing database, which is
routinely populated by the hospital pharmacy.
Should read:
In outpatients, systemic targeted therapies administered
as subcutaneous injections or orally are dispensed by the
hospital pharmacists to the patient, who will self-admin-
ister the drug. Systemic targeted therapies administered as
an intravenous infusion are administered exclusively in the
hospital setting, even to outpatients. However, the dis-
pensing of biological and non-biological targeted therapies
to outpatients is recorded at patient level through the dis-
pensing database, which is routinely populated by the
hospital pharmacy.
Section 2.3, 1st sentence, which previously read:
The biological drugs approved for cancer treatment and
available in Italy during the study years were classified into
mAbs, fusion proteins, immunomodulatory agents, and
small molecules, the latter being further categorized as
TKIs, mammalian target of rapamycin inhibitors (mTOR-
i), and proteasome inhibitors.
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Should read:
The biological and non-biological targeted therapies
approved for cancer treatment and available in Italy during
the study years were classified into mAbs, fusion proteins,
immunomodulatory agents, and small molecules, the latter
being further categorized as TKIs, mammalian target of
rapamycin inhibitors (mTOR-i), and proteasome inhibitors.
Section 2.4, 2nd paragraph, last line, which previously
read:
In addition, the pharmaceutical expenditure for the study
drugs was measured over time and stratified by type of
biological drug.
Should read:
In addition, the pharmaceutical expenditure for the study
drugs was measured over time and stratified by type of
drug.
Section 2.4, 3rd paragraph, 1st sentence, which previ-
ously read:
Users of different types of biological drug were char-
acterized in terms of age and sex, type of cancer, and
previous use of chemotherapeutics.
Should read:
Users of different types of study drugs were character-
ized in terms of age and sex, type of cancer, and previous
use of chemotherapeutics.
Table 1: There were errors in Table 1, below is the correct
version of Table 1:
Section 3, 3rd paragraph, which previously read:
During the study years, the total prevalence of use of
biological drugs for cancer treatment doubled from 0.9 (in
2010) to 1.8 (in 2014) per 1000 inhabitants, mostly due to
the increased use of small molecules (? 120.8%) rather
than mAbs (? 88.4%) (Fig. 1, Electronic Supplementary
Material Table S2).
Should read:
During the study years, the total prevalence of use of
study drugs for cancer treatment doubled from 0.9 (in
2010) to 1.8 (in 2014) per 1000 inhabitants, mostly due to
the increased use of small molecules (? 120.8%) rather
than mAbs (? 88.4%) (Fig. 1, Electronic Supplementary
Material Table S2).
Section 3, 4th paragraph, which previously read:
Accordingly, the costs of the biological drugs for cancer
treatment rapidly grew during the study years in Messina
Province from €6.6 million in 2010 (n = 591) to €13.6
million in 2014 (n = 1150), with a total expenditure of
around €50 million during the five observation years
(Fig. 2). Likewise, the number of different biological drugs
that were prescribed to the study population increased from
17 in 2010 to 21 in 2014 (data not shown).
Should read:
Accordingly, the costs of the biological and non-bio-
logical targeted therapies for cancer treatment rapidly grew
during the study years in Messina Province from €6.6
million in 2010 (n = 591) to €13.6 million in 2014 (n =
1150), with a total expenditure of around €50 million
during the five observation years (Fig. 2). Likewise, the
number of different biological and non-biological targeted
therapies that were prescribed to the study population
increased from 17 in 2010 to 21 in 2014 (data not shown).
Section 3, 5th paragraph, 1st sentence, which previously
read:
In 2020, based on our predictions, the expenditure for
biological study drugs will grow to €25 million.
Should read:
In 2020, based on our predictions, the expenditure for
monoclonal antibodies and other non-biological targeted
therapies will grow to €25 million.
Section 4, 1st paragraph, which previously read:
To our knowledge, this is the first observational study
investigating the prevalence of use and the costs of bio-
logical drugs in oncology in a large area of Southern Italy
using administrative healthcare databases.
Should read:
To our knowledge, this is the first observational study
investigating the prevalence of use and the costs of mon-
oclonal antibodies and other non-biological targeted ther-
apies in oncology in a large area of Southern Italy using
administrative healthcare databases.
Section 4, 2nd paragraph, which previously read:
Our results showed a dramatic increase in biological
drug use in oncology, considering both mAbs and small
molecules. These data are in line with the National Report
on Medicines Use in Italy in 2015 [9], which described an
18.2% increase in mAb consumption (ATC I level: L) in
comparison with the previous year. There may be different
reasons to explain the increasing number of cancer patients
using biological drugs. In recent years, an increasing
number of biological drugs have been marketed in Italy, as
confirmed by the increasing number of different ATCs for
cancer treatment dispensed in Messina during the study
years (from 17 in 2010 to 21 in 2014; data not shown).
Furthermore, many biological drugs already approved for
cancer treatment gained an extension to their indications of
use, thus guaranteeing access to these innovative therapies
to a larger number of patients. We observed an increase in
the number of prevalent users over time, despite a decrease
in the proportion of incident users (from 61.4% in 2011 to
54.4% in 2014; data not shown). These results reflect a
growing number of patients taking biological drugs for a
longer period of time, rather than an increase in those
initiating treatment. During the study years, no users of
fusion proteins or immunomodulatory agents could be
Author Correction to: Cost of Biological and Non-Biological Targeted Therapies in Oncology in Southern Italy
Table 1 Characteristics of users of monoclonal antibodies and other non-biological targeted therapies (i.e. small molecules) for cancer
treatment in the years 2010–2014 in Messina Province
Characteristic mAbs
(n = 1607)
Small molecules Total
(n = 2491)
TKIs
(n = 609)
Proteasome
inhibitors
(n = 203)
mTOR-i
(n = 72)
Total
(n = 884)
Sex
Male 638 (39.7) 382 (62.7) 95 (46.8) 21 (29.2) 498 (56.3) 1136 (45.6)
Female 969 (60.3) 227 (37.3) 108 (53.2) 51 (70.8) 386 (43.7) 1355 (56.4)
Age (years) [median (Q1–Q3)] 62 (53–71) 65 (56–74) 70 (61–77) 63 (54.5–71.5) 67 (58–75) 64 (54–72)
Age categories (years)
\ 45 158 (9.8) 44 (7.2) 3 (1.5) 4 (5.6) 51 (5.7) 209 (8.4)
45–64 759 (47.2) 246 (40.4) 60 (29.6) 35 (48.6) 341 (38.6) 1100 (44.2)
65–79 589 (36.7) 265 (43.5) 113 (55.7) 26 (36.1) 404 (45.7) 993 (39.9)
C 80 101 (6.3) 54 (8.9) 27 (13.3) 7 (9.7) 88 (10.0) 189 (7.5)
Follow-up (days) [median (Q1–Q3)] 327 (130–595) 313 (91–867) 320 (132–644) 225 (69–358.5) 305 (95.5–777) 319 (119–640)
Number of dispensing of the study
drugs at ID [median (Q1–Q3)]
7 (3–14) 4 (2–12) 16 (8–25) 3 (1–6) 5 (2–16) 6 (3–14)
Type of cancera
Lymphatic tissueb 268 (16.7) 2 (0.3) 3 (1.5) 5 (0.6) 273 (11.0)
Breast (female) 220 (13.7) 10 (1.6) 4 (5.6) 14 (1.6) 234 (9.4)
Colorectal 148 (9.2) 3 (0.5) 3 (0.3) 151 (6.1)
Leukemia 77 (4.8) 84 (13.8) 84 (9.5) 161 (6.5)
Lung 24 (1.5) 79 (13.0) 79 (8.9) 103 (4.1)
Liver cancer 5 (0.3) 48 (7.9) 48 (5.4) 53 (2.1)
Multiple myeloma 4 (0.2) 116 (57.1) 116 (13.1) 120 (4.8)
Metastasis of unspecified
primary tumor
389 (24.2) 102 (16.7) 1 (0.5) 8 (11.1) 111 (12.6) 500 (20.1)
Other types of cancerc 124 (7.7) 55 (9.0) 14 (6.9) 5 (6.9) 74 (8.4) 198 (7.9)
Not reported 348 (21.7) 226 (37.1) 69 (34.0) 55 (76.4) 350 (39.6) 698 (28.0)
Previous chemotherapyd
Number of chemotherapeutics
0 916 (57.0) 517 (84.9) 193 (95.1) 34 (47.2) 744 (84.2) 1660 (66.6)
1 220 (13.7) 49 (8.0) 9 (4.4) 34 (47.2) 92 (10.4) 312 (12.5)
2–3 422 (26.3) 42 (6.9) 1 (0.5) 4 (5.6) 47 (5.3) 469 (18.9)
C4 49 (3.0) 1 (0.2) 1 (0.1) 50 (2.0)
Type of chemotherapeutics
Cyclophosphamide 342 (21.3) 1 (0.2) 1 (0.5) 2 (0.2) 344 (13.8)
Fluorouracil 234 (14.6) 1 (0.2) 1 (1.4) 2 (0.2) 236 (9.5)
Doxorubicin 153 (9.5) 7 (3.9) 4 (5.6) 11 (1.2) 164 (6.6)
Epirubicin 161 (10.0) 1 (0.2) 1 (0.1) 162 (6.5)
Docetaxel 128 (8.0) 17 (2.8) 2 (2.8) 19 (2.1) 147 (5.9)
Vincristine 99 (6.2) 2 (1.0) 2 (0.2) 101 (4.1)
Oxaliplatin 71 (4.4) 1 (1.4) 1 (0.1) 72 (2.9)
Capecitabine 40 (2.5) 14 (2.3) 4 (5.6) 18 (2.0) 58 (2.3)
Paclitaxel 51 (3.2) 1 (0.2) 3 (4.2) 4 (0.5) 55 (2.2)
Gemcitabine 12 (0.7) 34 (5.6) 2 (2.8) 36 (4.1) 48 (1.9)
Vinorelbine 14 (0.9) 23 (3.8) 7 (9.7) 30 (3.4) 44 (1.8)
Carboplatin 17 (1.1) 24 (3.9) 1 (1.4) 25 (2.8) 42 (1.7)
Triptorelin 32 (2.0) 5 (0.8) 2 (2.8) 7 (0.8) 39 (1.6)
Fulvestrant 19 (1.2) 10 (13.9) 10 (1.1) 29 (1.2)
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identified. Specifically, use of aflibercept has only been
approved in Sicily since November 2014 and we therefore
could not identify any users of this drug. Due to their costs,
many biological drugs in oncology are included among the
top 30 molecules for drug expenditure sustained by public
hospitals, with trastuzumab, bevacizumab, and rituximab
being the top three.
Should read:
Our results showed a dramatic increase in biological and
non-biological targeted therapies use in oncology, consid-
ering both mAbs and small molecules. These data are in
line with the National Report on Medicines Use in Italy in
2015 [9], which described an 18.2% increase in mAb
consumption (ATC I level: L) in comparison with the
previous year. There may be different reasons to explain
the increasing number of cancer patients using the study
drugs. In recent years, an increasing number of biological
and non-biological targeted therapies have been marketed
in Italy, as confirmed by the increasing number of different
ATCs for cancer treatment dispensed in Messina during the
study years (from 17 in 2010 to 21 in 2014; data not
shown). Furthermore, many biological and non-biological
targeted therapies already approved for cancer treatment
gained an extension to their indications of use, thus guar-
anteeing access to these innovative therapies to a larger
number of patients. We observed an increase in the number
of prevalent users over time, despite a decrease in the
proportion of incident users (from 61.4% in 2011 to 54.4%
in 2014; data not shown). These results reflect a growing
number of patients taking monoclonal antibodies and other
non-biological targeted therapies (small molecules) for a
longer period of time, rather than an increase in those
initiating treatment. During the study years, no users of
fusion proteins or immunomodulatory agents could be
identified. Specifically, use of aflibercept has only been
approved in Sicily since November 2014 and we therefore
could not identify any users of this drug. Due to their costs,
many targeted therapies in oncology are included among
the top 30 molecules for drug expenditure sustained by
public hospitals, with trastuzumab, bevacizumab, and
rituximab being the top three.
Figure 1 legend, which previously read:
Prevalence of biological drugs use for cancer treatment
per 1000 inhabitants, stratified by calendar year. mAb
monoclonal antibodies, mTOR mammalian target of rapa-
mycin, TKI tyrosine kinase inhibitors
Should read:
Prevalence of biological and non-biological targeted
therapies use for cancer treatment per 1000 inhabitants,
stratified by calendar year. mAb monoclonal antibodies,
mTOR mammalian target of rapamycin, TKI tyrosine
kinase inhibitors
Table 1 continued
Characteristic mAbs
(n = 1607)
Small molecules Total
(n = 2491)
TKIs
(n = 609)
Proteasome
inhibitors
(n = 203)
mTOR-i
(n = 72)
Total
(n = 884)
Bendamustine 27 (1.7) 27 (1.1)
Fludarabine 25 (1.6) 25 (1.0)
Otherse 54 (3.4) 24 (3.9) 2 (1.0) 6 (8.3) 32 (3.6) 86 (3.5)
Data are given as n (%) unless otherwise specified
Patients (n = 8) who were dispensed two different drugs at the index date were excluded
Patients (n = 2) whose sex and age were not available were excluded
No users of fusion proteins or immunomodulatory agents could be identified during the study years, and these two drug categories are therefore
not included
ID index date, mAb monoclonal antibodies, mTOR-i mammalian target of rapamycin inhibitors, Q1–Q3 interquartile range, TKIs tyrosine-kinase
inhibitors
aType of cancer refers to the last cancer diagnosis registered within 6 months prior to the first dispensing of the study drugs, during the study
period
bNeoplasms of lymphatic tissue include lymphosarcoma and reticulosarcoma, Hodgkin’s disease, non-Hodgkin’s lymphoma
cOther neoplasms include neoplasms of peritoneum, eye, brain, thyroid, bones and connective tissue, genitourinary system, pancreas, respiratory
organs (other than lungs), skin, carcinomas in situ, monoclonal gammopathy, prostate, benign neoplasm, breast (males), bladder and kidney,
esophagus, stomach, duodenum, trachea, larynx, nasal cavities and neoplasms of unspecified nature
dChemotherapeutics were identified within 6 months prior to the first dispensing of the study drugs, during the study period
eOther chemotherapeutics include cisplatin, pemetrexed, vinblastine, temozolomide, bleomycin, dacarbarzine, methotrexate, etoposide, eribulin,
topotecan, azacitidine, cabazitaxel, mitoxantrone, tegafur, vindesine, fotemustine
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Figure 2 legend, which previously read:
Expenditure for the dispensing of biological drugs in
oncology in Messina Province in the years 2010–2014,
stratified by calendar year and type of biological drugs.
mAb monoclonal antibodies, mTOR-i mammalian target of
rapamycin inhibitors, proteas-i proteasome inhibitors, TKI
tyrosine kinase inhibitors
Should read:
Expenditure for the dispensing of biological and non-
biological targeted therapies in oncology in Messina Pro-
vince in the years 2010–2014, stratified by calendar year
and type of drug. mAb monoclonal antibodies, mTOR-i
mammalian target of rapamycin inhibitors, proteas-i pro-
teasome inhibitors, TKI tyrosine kinase inhibitors. The
purple line indicates the number of patients receiving the
study drugs
Figure 3 legend, which previously read:
Prevision of expenditure for biological drugs for cancer
treatment in Messina area, assuming an uptake of trastu-
zumab and rituximab biosimilars of 0, 20, 50, and 80%
Should read:
Prevision of expenditure for biological and non-biolog-
ical targeted therapies for cancer treatment in Messina area,
assuming an uptake of trastuzumab and rituximab
biosimilars of 0, 20, 50, and 80%
Section 4, 4th paragraph, which previously read:
The assumptions taken into account for the forecast of
the expected expenditure on biological drugs in oncology
until 2020 are as follows:
Should read:
The assumptions taken into account for the forecast of
the expected expenditure on monoclonal antibodies plus
other non-biological targeted therapies drugs in oncology
until 2020 are as follows:
Section 4, 7th paragraph, 3rd line, which previously read:
On the other hand, the future marketing of innovative
and highly priced biological drugs for the treatment of
cancer will likely increase pharmaceutical expenditure.
Should read:
On the other hand, the future marketing of innovative
and highly priced drugs for the treatment of cancer will
likely increase pharmaceutical expenditure.
Section 4, 7th paragraph, last line, which previously
read:
In addition, patients treated first with the study biolog-
ical drugs or with the corresponding biosimilars may
switch to newly marketed innovative drugs, thus leading to
an increase in total expenditure and to a lower uptake of
biosimilars.
Should read:
In addition, patients treated first with the study
drugs or with the biosimilars may switch to newly
marketed innovative drugs, thus leading to an increase
in total expenditure and to a lower uptake of
biosimilars.
Section 4, 9th paragraph, 1st line, which previously read:
In such a context, post-marketing monitoring systems
using real-world data may allow rapid evaluations of the
uptake, appropriate use, safety, and economic impact of the
high-cost biological drugs and their corresponding
biosimilars in cancer patients, thus optimizing pharma-
ceutical expenditure.
Should read:
In such a context, post-marketing monitoring systems
using real-world data may allow rapid evaluations of the
uptake, appropriate use, safety, and economic impact of the
high-cost biological drugs and their corresponding
biosimilars as well as other non-biological innovative tar-
geted therapies in cancer patients, thus optimizing phar-
maceutical expenditure.
Section 4, 9th paragraph, 2nd line, which previously
read:
For most of the biological drugs approved for cancer
treatment, the Italian Drug Agency implemented drug-
specific monitoring registries as tools to monitor the
appropriate use, effectiveness, and safety of those drugs
that may facilitate post-marketing monitoring, although so
far these registries have not been systematically used for
scientific purposes [19].
Should read:
For most of the monoclonal antibodies and other non-
biological targeted therapies approved for cancer treat-
ment, the Italian Drug Agency implemented drug-specific
monitoring registries as tools to monitor the appropriate
use, effectiveness, and safety of those drugs that may
facilitate post-marketing monitoring, although so far these
registries have not been systematically used for scientific
purposes [19].
Section 4.1, 1st paragraph, 1st line, which previously
read:
Using administrative healthcare databases, including
dispensing data and the hospital discharge diagnosis, this
observational study investigated the prevalence of use and
the costs of biological drugs in oncology in a large area
from Southern Italy, covering a population of more than
650,000 people.
Should read:
Using administrative healthcare databases, including
dispensing data and the hospital discharge diagnosis, this
observational study investigated the prevalence of use
and the costs of biological and non-biological targeted
therapies in oncology in a large area from Southern
Italy, covering a population of more than 650,000
people.
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Section 4.1, 1st paragraph, last line, which previously
read:
Due to the frequency of administration, especially for
infusion biological drugs, patients are much more likely to
choose the closest oncology center.
Should read:
Due to the frequency of administration, especially for
infusion study drugs, patients are much more likely to
choose the closest oncology center.
Section 5, 1st line, which previously read:
The use of and corresponding expenditure relating to
biological drugs for cancer treatment has rapidly and dra-
matically increased, almost doubling over a 5-year period
in a large general population of Southern Italy.
Should read:
The use of and corresponding expenditure relating to
monoclonal antibodies and other non-biological targeted
therapies for cancer treatment has rapidly and dramatically
increased, almost doubling over a 5-year period in a large
general population of Southern Italy.
Section 5, last line, which previously read:
On the other hand, real-world data are essential to
rapidly monitor the benefit–risk profile and appropriate use
of biological drugs and related biosimilars in routine care,
with the final goal being to optimize pharmaceutical
expenditure in oncology patients.
Should read:
On the other hand, real-world data are essential to
rapidly monitor the benefit–risk profile and appropriate use
of monoclonal antibodies and related biosimilars as well as
other non-biological targeted therapies in routine care, with
the final goal being to optimize pharmaceutical expenditure
in oncology patients. Electronic Supplementary Materials
Table S1 caption, which previously read: Biological drugs
for cancer treatment available on the market, in the study
period.
Should read:
Biological and non-biological targeted therapies for
cancer treatment available on the market, in the study
period.
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